SCHEMBL10136212

SCHEMBL10136212

CC(=O)NC1C(OC(C)=O)OC(COC(C)=O)[C@@H](O[C@@H]2OC(COC(C)=O)[C@H](OC(C)=O)[C@H](OC(C)=O)C2OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.62
▸ KMT2A Q03164 1/20 0.62
▸ POLB P06746 2/20 0.58
▸ ALDH1A1 P00352 2/20 0.58
▸ CYP2D6 P10635 1/20 0.55
▸ THRB P10828 1/20 0.55
▸ HSD17B10 Q99714 1/20 0.55
▸ CYP3A4 P08684 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ CA2 P00918 11/20 0.50
▸ CA12 O43570 10/20 0.50
▸ CA1 P00915 10/20 0.50
▸ CA9 Q16790 10/20 0.50
▸ CA14 Q9ULX7 4/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ NR3C1 P04150 1/20 0.48
▸ FYN P06241 1/20 0.48
▸ ADRA2A P08913 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13308249 1.00 LMNA (0.62) LMNAKMT2APOLBALDH1A1CYP2D6
SCHEMBL10705633 1.00 LMNA (0.62) LMNAKMT2APOLBALDH1A1CYP2D6
SCHEMBL10526835 1.00 LMNA (0.62) LMNAKMT2APOLBALDH1A1CYP2D6
SCHEMBL10705947 1.00 LMNA (0.62) LMNAKMT2APOLBALDH1A1CYP2D6
SCHEMBL10167799 1.00 LMNA (0.62) LMNAKMT2APOLBALDH1A1CYP2D6
SCHEMBL29838800 1.00 LMNA (0.62) LMNAKMT2APOLBALDH1A1CYP2D6
SCHEMBL31068056 0.95 LMNA (0.64) LMNAKMT2APOLBALDH1A1CYP2D6
SCHEMBL4399197 0.95 LMNA (0.64) LMNAKMT2APOLBALDH1A1CYP2D6
SCHEMBL25788683 0.95 LMNA (0.64) LMNAKMT2APOLBALDH1A1CYP2D6
SCHEMBL25788745 0.95 LMNA (0.64) LMNAKMT2APOLBALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207328-B2 Lactosamine derivatives GLYCOM APS (DK) 2012-06-26 — — US disclosed
US-20090234111-A1 Novel Lactosamine Derivatives GLYCOM APS (DK) 2009-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090234111-A1 Novel Lactosamine Derivatives B3GNT2, FUT6, FUT5 LMNA 332/4885KMT2A 2187/4885POLB 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback